Quick Dispatch:
Your semaglutide heart failure trial Anti-Obesity Medications in Patients With Heart Failure: Current Evidence and Practical Guidance orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your semaglutide heart failure trial Anti-Obesity Medications in Patients With Heart Failure: Current Evidence and Practical Guidance ships.
Need Help?
Questions about semaglutide heart failure trial Anti-Obesity Medications in Patients With Heart Failure: Current Evidence and Practical Guidance, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for semaglutide heart failure trial Anti-Obesity Medications in Patients With Heart Failure: Current Evidence and Practical Guidance in your area.
Semaglutide treatment reduces heart failure risks
25.84
Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial
23.30
01643-X/asset/61d4b1e3-2f49-4c43-b92a-74e0847683f2/main.assets/gr2_lrg.jpg)
Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials
22.48
Wegovy shown to reduce risk of heart attack, stroke in major cardiovascular trial
28.53
Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial
21.73
Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial
20.27
Impact of Semaglutide 2.4 mg on Healthcare Resource Utilization and Medical Costs in Patients With Heart Failure in the United States (SHINE-HF)
22.98
